ExploRNA Therapeutics is pioneering the use of mRNA as a therapeutic platform, leveraging its innovative technologies to develop advanced treatments for various diseases. The company focuses on creating tailored mRNA solutions, particularly through its proprietary cap analogs, ExploCap® and AvantCap®. These cap analogs enhance the stability and efficacy of mRNA, facilitating the development of mRNA-based vaccines and therapeutics. By utilizing mRNA's ability to deliver specific genetic instructions to cells, ExploRNA aims to revolutionize drug discovery and manufacturing, offering a versatile approach to treating a wide range of conditions.

The company's research and development efforts are centered on two primary areas: the innovation of mRNA platforms and the creation of mRNA-based therapeutic programs. ExploRNA's team of experts, with extensive backgrounds in chemical biology and immunology, is dedicated to harnessing the potential of modified mRNA to address unmet medical needs. Their lead development programs focus on tumor-specific antigen vaccines and cytokine expression to enhance immune responses against cancer. With a strong intellectual property portfolio and strategic collaborations, ExploRNA Therapeutics is positioned to make significant contributions to the field of mRNA medicine.

Poland

Our mission is to deliver mRNA technology innovations to revolutionize future therapies and the prevention of many diseases. We invent, develop, manufacture and apply our solutions for the benefit of pharmaceutical partners, and to improve people’s lives.

With passion, ExploRNA Therapeutics develops ground-breaking innovations of mRNA as a therapeutic platform, applies those solutions in unique therapeutic programs, and delivers technology, therapeutic platform, and therapies to pharmaceutical partners.

ExploRNA Therapeutics

Company Details